Expression of MUM1, BCL-6, and CD138/syn-1 andBCL-6 gene mutations in AIDS-related primary effusion lymphoma and AIDS-related plasmablastic lymphoma
| Case . | Diagnosis . | Immunohistochemistry . | BCL-6 (mut) . | EBV . | |||
|---|---|---|---|---|---|---|---|
| MUM13-150 . | BCL-63-150 . | Syn-13-150 . | EBER . | LMP13-150 . | |||
| 1 | PEL | 25-50 | ne | − | − | + | < 10 |
| 2 | PEL | > 75 | − | > 75 | − | + | < 10 |
| 3 | PEL | > 75 | − | > 75 | − | − | nd |
| 4 | PEL | 50-75 | − | > 75 | + | + | − |
| 5 | PEL | > 75 | − | > 75 | + | − | − |
| 6 | PEL | 50-75 | − | > 75 | + | + | < 10 |
| 7 | PEL | 25-50 | − | > 75 | + | − | − |
| 8 | PEL | 50-75 | − | 25-50 | − | + | − |
| 9 | PEL | > 75 | − | > 75 | − | + | − |
| 10 | PEL | > 75 | − | > 75 | + | + | − |
| 11 | PEL | > 75 | − | > 75 | − | − | − |
| 1 | PBL | > 75 | − | > 75 | nd | + | − |
| 2 | PBL | > 75 | − | 50-75 | nd | + | − |
| 3 | PBL | > 75 | − | > 75 | nd | + | − |
| 4 | PBL | > 75 | − | > 75 | nd | + | − |
| 5 | PBL | > 75 | − | > 75 | nd | − | − |
| 6 | PBL | > 75 | − | > 75 | nd | + | − |
| 7 | PBL | 10-25 | − | 25-50 | nd | + | − |
| Case . | Diagnosis . | Immunohistochemistry . | BCL-6 (mut) . | EBV . | |||
|---|---|---|---|---|---|---|---|
| MUM13-150 . | BCL-63-150 . | Syn-13-150 . | EBER . | LMP13-150 . | |||
| 1 | PEL | 25-50 | ne | − | − | + | < 10 |
| 2 | PEL | > 75 | − | > 75 | − | + | < 10 |
| 3 | PEL | > 75 | − | > 75 | − | − | nd |
| 4 | PEL | 50-75 | − | > 75 | + | + | − |
| 5 | PEL | > 75 | − | > 75 | + | − | − |
| 6 | PEL | 50-75 | − | > 75 | + | + | < 10 |
| 7 | PEL | 25-50 | − | > 75 | + | − | − |
| 8 | PEL | 50-75 | − | 25-50 | − | + | − |
| 9 | PEL | > 75 | − | > 75 | − | + | − |
| 10 | PEL | > 75 | − | > 75 | + | + | − |
| 11 | PEL | > 75 | − | > 75 | − | − | − |
| 1 | PBL | > 75 | − | > 75 | nd | + | − |
| 2 | PBL | > 75 | − | 50-75 | nd | + | − |
| 3 | PBL | > 75 | − | > 75 | nd | + | − |
| 4 | PBL | > 75 | − | > 75 | nd | + | − |
| 5 | PBL | > 75 | − | > 75 | nd | − | − |
| 6 | PBL | > 75 | − | > 75 | nd | + | − |
| 7 | PBL | 10-25 | − | 25-50 | nd | + | − |
PEL indicates primary effusion lymphoma; ne, not evaluable; PBL, plasmablastic lymphoma; see Table 1 for other abbreviations.
Percentages of MUM1, BCL-6, syn-1, and LMP1+ neoplastic cells were assigned to one of the following categories: 0%, less than 10%, 10% to 25%, 25% to 50%, 50% to 75%, and greater than 75%.